Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05046184 · ClinicalTrials.gov registry record · Phase 2
Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT05046184 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 165 participants.
The verdict
NCT05046184, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
The study is investigating dysfunctions in neurocircuitry in regards to irritability with healthy controls (HC) and individuals with Major Depressive Disorder (MDD) by performing MRIs. The MDD group will also be randomized to receive ketamine or midazolam to investigate changes post-treatment in neurocircuitry with regards to irritability.
Interventions
- DRUG Ketamine Hydrochloride
- DRUG Midazolam injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2022-05-05 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05046184
The ClinicalTrials.gov registry entry for NCT05046184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine Hydrochloride is the first listed.
NCT05046184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05046184 about?
NCT05046184 is a clinical study titled "Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets". The study is investigating dysfunctions in neurocircuitry in regards to irritability with healthy controls (HC) and individuals with Major Depressive Disorder (MDD) by performing MRIs. The MDD group will also be randomized to receive ketamine or midazolam to investigate changes post-treatment in neu...
What is the current status of trial NCT05046184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2022-05-05. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT05046184?
The interventions under investigation include: Ketamine Hydrochloride (DRUG), Midazolam injection (DRUG).
Who is sponsoring clinical trial NCT05046184?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.